Class I Medical Therapies for CAD and PAD

Slides:

Advertisements

Similar presentations

What Have We Learned from the CRUSADE Registry

Advertisements

North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.

Technology and Expenditure Growth in Health Care Amitabh Chandra HARVARD UNIVERSITY.

Cardiac Issues With Noncardiac Surgery Joseph F. Winget, MD FACC Clinical Assistant Professor University of Vermont Medical School Champlain Valley Cardiovascular.

Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.

© 2002, Wellsource Inc. C-Reactive Protein A New Test for Cardiovascular Risk Prepared by Don Hall, DrPH Wellsource Inc.

Redwood Community Care Organization Data Capture for ACO Quality Measures.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Data Input Manual ACO Specific Quality Measures. Table of Contents Selection of Attributed ACO Patient…………………………………………………………...…….1 Section of Proper.

Major Bleeding Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian,

Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.

C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.

Claims-Based Quality Measures CMS Physician Group Practice Demonstration Project Chealsea Nather 26 January 2005.

BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.

CardioVascular Disease Prevention. CVD prevention ‘The evidence that most cardiovascular disease is preventable continues to grow.’ ‘The evidence that.

RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.

Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,

Cardiac Rehabilitation 2011 Update for Primary Care Providers Douglass A Morrison, MD, PhD Cardiac Rehabilitation, Medical Director Yakima Regional and.

What’s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 13.

Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.

Multivessel Coronary Artery Disease

Management Strategies for Post-Intervention in Patients with CAD VBWG.

Transitions in Care-Heart Failure

Case Study CAD Equivalent

_________________ Caitlin M. Gibson, PharmD, BCPS

Disclosures Speaker’s bureau: Research support: Consulting: Equity

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

When should aspirin be dropped from triple therapy?

Andre Lamy on behalf of the COMPASS Investigators

Preventing Thrombotic Complications in ACS: State of the Art

Medical Therapy for Peripheral Artery Disease

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Glenn N. Levine et al. JACC 2016;68:

A New Era for NOACs:.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Glenn N. Levine et al. JACC 2016;68:

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

New Perspectives in CAD and PAD: Weighing the Latest Evidence

بسم الله الرحمن الرحيم الموضوع:الوضوء صفته وفرائضه وسننه

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Terms of Use. Terms of Use.

Treatment Options to Consider

NOACS: Emerging data in ACS/IHD

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

Would you recommend extending DAPT >1 year post-MI?

2006 CRUSADE 2nd Quarter Results

CV Risk Doesn't End in the Cath Lab

ISAR-SAFE Trial design: Patients with DES PCI received 6 months of open-label DAPT with aspirin and clopidogrel. At 6 months, they were randomized in a.

Exercise-Based Cardiac Rehabilitation and Improvements in Cardiorespiratory Fitness: Implications Regarding Patient Benefit Barry A. Franklin, PhD Mayo.

Preventive Angioplasty in Myocardial Infarction Trial

The European Society of Cardiology Presented by RJ De Winter

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

CAD and HF Often Coexist

Anemia Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian, George.

Factor Xa Inhibitors in Coronary Artery Disease

REF222 Danvers Diabetes Referral (CMS)

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges

Ahmed A. Khattab, MD For the German Cypher Registry Investigators

Glenn N. Levine et al. JACC 2011;58:e44-e122

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

ESC Guideline on the Management of STEMI Recommendation for DAPT

Dyslipidemia And Diabetes

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

Cardiovascular Epidemiology and Epidemiological Modelling

Clinical Case Gilles Montalescot

Presentation transcript:

Class I Medical Therapies for CAD and PAD Aspirin alone DAPT after PCI or ACS Statin therapy Anti-HTN therapy Tobacco cessation/avoidance Diabetes management Influenza Vaccine Home-based exercise Cardiac Rehabilitation after ACS, CABG, or PCI Weight loss Aspirin alone or Clopidogrel alone Statin therapy Anti-HTN therapy Tobacco cessation/avoidance Diabetes management Influenza vaccine Supervised exercise program JACC 2017;69:e71-126 JACC 2011;58:2432-46

COMPASS: Rivaroxaban in stable CAD and PAD All Patients PAD Patients Only NEJM 2017; 377:1319-1330 Lancet 2017; 391:219-229

Exercise for PAD vs. Cardiac Rehabilitation JACC 2017;69:e71-126